Krabbe Disease – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Krabbe disease is a lysosomal disorder that affects the white matter of the central and peripheral nervous systems. It includes infantile, late-infantile/juvenile, and adult forms.
Etiology-
Krabbe disease is caused
by changes (mutations) in the GALC gene. This gene provides instructions for
making an enzyme called galactosylceramidase, which breaks down a certain type
of fat that is primarily found in the brain and kidneys. Mutations in the GALC
gene lead to reduced levels of the galactosylceramidase enzyme which can cause
a build-up of toxic fats in the cells of the brain and other tissues.
Rarely, infantile Krabbe
disease is caused by a mutation in the prosaposin (PSAP) gene (10q21-q22),
encoding sphingolipid activator protein saposin-A, necessary for GALC activity.
Epidemiology-
It has an estimated
prevalence of 1/100,000 in the Northern European population (higher in certain
populations) and a worldwide incidence of 1/100,000-1/250,000 live births. The
infantile form is the most common form and accounts for 85-90% of cases in the
Northern European population.
The competitive
landscape of Krabbe Disease includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs
insights of Krabbe Disease across 8 MM market from the center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Krabbe
Disease Market Forecast: Patient Based Forecast Model (MS. Excel
Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
S. No Asset Company Stage
1 FBX-101 Forge
Biologics, Inc Phase 1/2
2 PBKR03 Passage
Bio, Inc. Phase 1/2
3 MGTA-456 Magenta
Therapeutics, Inc. Phase 2
Comments
Post a Comment